Gilead Sciences is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Its core products include antiviral therapies for HIV, hepatitis B, hepatitis C, and influenza, as well as treatments for cancer and inflammatory diseases. Major business segments consist of antiviral and oncology products, with primary revenue sources stemming from sales of these therapies. The company is recognized for its contributions to public health through its advanced drug formulations and research initiatives.
Gilead Sciences presents a profile more aligned with dividend investors due to its consistent dividend yield. The stock may appeal to those seeking income rather than aggressive growth, given its established market presence and product portfolio. However, recent revenue declines suggest caution for value investors. The stock may suit a balanced approach, considering its potential for moderate returns alongside dividend income.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-06 | Hold | Buy | Solid fundamentals, but recent revenue decline raises concerns. |
| 2026-08-29 | Buy | Hold | Mixed performance; cautious due to revenue decline. |
| 2026-08-20 | Hold | Buy | Strong momentum and solid dividend yield support growth. |
| 2026-08-10 | Sell | Hold | Mixed performance; cautious due to revenue decline. |
| 2026-07-29 | Hold | Sell | Mixed performance; cautious outlook amid revenue decline. |
| 2026-07-21 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-07-13 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-17 | Sell | Hold | Mixed performance; cautious outlook amid revenue decline. |
| 2026-06-09 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-01 | Buy | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-24 | Hold | Buy | Mixed performance; cautious due to revenue decline. |
| 2026-05-22 | Sell | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-10 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 | — | Hold | Stable earnings but mixed momentum and sector pressure. |
| 2026-05-03 | Hold | Buy | Компания демонстрирует стабильный рост выручки и дивидендную доходность, однако недавнее снижение цен акций и негативная динамика на более длительных сроках могут указывать на риски. |
| 2026-04-25 | Buy | Hold | Компания Gilead Sciences демонстрирует стабильный рост выручки и дивидендную доходность, однако недавние колебания цен акций и риск волатильности на рынке требуют осторожного подхода. |
| 2026-03-30 | Hold | Buy | Компания демонстрирует стабильный рост выручки и положительные показатели за последние 120 дней, что указывает на потенциал для дальнейшего роста. Дивидендная доходность также привлекательна, что делает акции интересными |
| 2026-03-23 | Buy | Hold | Компания демонстрирует стабильный рост выручки и дивидендную доходность, однако недавние колебания цен и снижение на коротких временных интервалах указывают на определенные риски. |
| 2026-01-23 | Hold | Buy | Компания Gilead Sciences демонстрирует положительную динамику цен на акции и имеет потенциал для роста благодаря своим инновационным продуктам в области здравоохранения. Низкий риск обусловлен стабильным спросом на лекар |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-05 | Truist Financial | Target Lowered | 156 → 150 | 132.755 |
| 2026-08-05 | RBC Capital | Target Raised | 120 → 123 | 135.25 |
| 2026-07-29 | Barclays | Target Lowered | 155 → 145 | 134.32 |
| 2026-07-27 | Morgan Stanley | Target Lowered | 166 → 165 | 131.23 |
| 2026-07-20 | Leerink Partners | Rating Downgraded | — → 127 | 133.21 |
| 2026-07-08 | Morgan Stanley | Target Lowered | 168 → 166 | 136.36 |
| 2026-07-07 | RBC Capital | Target Lowered | 122 → 120 | 129.61 |
| 2026-07-06 | HSBC | Update | — → 155 | 131.27 |
| 2026-06-01 | RBC Capital | Update | — → 122 | 134.43 |
| 2026-05-20 | Maxim Group | Rating Upgraded | — → 165 | 130.5492 |
| 2026-05-10 | Morgan Stanley | Target Lowered | 175 → 168 | 131.33 |
| 2026-05-08 | Truist Financial | Target Raised | 155 → 157 | 132.025 |
| 2026-04-10 | Morgan Stanley | Target Raised | 171 → 175 | 140.34 |
| 2026-04-08 | Truist Financial | Target Raised | 152 → 155 | 141.54 |
| 2026-03-10 | Jefferies | Update | — → 180 | 146.935 |
| 2026-02-19 | Barclays | Update | — → 155 | 151.12 |
| 2026-02-19 | Mizuho Securities | Target Raised | 140 → 170 | 152.74 |
| 2026-02-18 | UBS | Target Raised | 155 → 175 | 155.27 |
| 2026-02-11 | Scotiabank | Target Raised | 140 → 177 | 155.29 |
